A PYMNTS Company

UK: Eye correction merger referred to Competition Commission

By  |  August 6, 2013

The UK’s Office of Fair Trading announced the referral of the completed buyout of eye correction company Ultralase by competitor Optimax to the Competition Commission in what reports say suggests the OFT may have found cause of concern regarding the deal. The deal occurred in November of last year without informing the OFT; it was not until the companies’ merger was undeway that the regulator started probing the buyout. Reports say by the initiation of the review, several Ultralase clinics were already replaced by Optimax clinics. In its review, the OFT found six geographical areas whose competition was threatened by the deal. Reports say the Commission will reach a decision on the deal by January 12 of next year.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full Content: OptometryToday

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.